All In Biotech

Drug Trial Radar · NCT07862465

Medical Access Program for Valemetostat Tosylate (DS 3201b) For The Treatment of Patients With Relapsed/Refractory (R/R) Peripheral T-cell Lymphoma (PTCL)

Medical Access Program for Valemetostat Tosylate (DS 3201b) For The Treatment of Patients With Relapsed/Refractory (R/R) Peripheral T-cell Lymphoma (PTCL) Originating From Mature T Cells (Including But Not Limited to Adult T-cell Leukemia/Lymphoma [ATLL], Anaplastic Large Cell Lymphoma [ALCL], Refractory Nodal T-Follicular Helper Lymphoma [nTFHL]), Regardless of CD30 Who Have Failed on 2 or More Lines of Treatments

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Available

Status

Available

Enrollment

Not stated

Start

Not stated

Primary completion

Not stated

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
First posted
Oct 7, 2026

More drug trials from this sponsor

Design

Study type
Expanded access
Who can join
All sexes, from 18 years

Summary

As written by the sponsor on the registry.

Valemetostat tosylate demonstrates antitumour activity in patients with peripheral T-cell lymphomas (PTCL) with a manageable safety profile. This Medical Access Program (MAP) offers an alternative treatment option for patients with PTCL who are ineligible for clinical trials by providing access to valmetostat tosylate, a medicinal product that has received marketing authorisation in Japan.

Conditions

  • Peripheral T-cell Lymphomas
  • Adult T-cell Leukemia/Lymphoma
  • Anaplastic Large Cell Lymphoma
  • Refractory Nodal T-follicular Helper Lymphoma

Interventions

  • Valemetostat tosylateDrug

    In this MAP, the recommended starting dose for eligible patients is 200 mg of valemetostat tosylate once daily in continuous 28-day cycles, to be continued until disease progression or unacceptable toxicity.

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.